Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.55 |
| ▸ | LIPE | Q05469 | 2/20 | 0.46 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.44 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.44 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956826 | 1.00 | ENPP2 (0.55) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL29955587 | 0.92 | ENPP2 (0.52) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL21979744 | 0.92 | ENPP2 (0.52) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL27043162 | 0.91 | ENPP2 (0.50) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL2552732 | 0.88 | KAT2B (0.56) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL28414854 | 0.83 | ENPP2 (0.41) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL31483706 | 0.82 | ENPP2 (0.40) | ENPP2LIPEORAI1ORAI2ORAI3 | |
| SCHEMBL29952605 | 0.81 | KAT2B (0.47) | ENPP2LIPEKAT2BBAZ2B | |
| SCHEMBL18981913 | 0.81 | ENPP2 (0.38) | ENPP2ORAI1ORAI2ORAI3KAT2B | |
| SCHEMBL21767584 | 0.78 | SCD (0.39) | LIPEHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | SCHR¿DINGER, LLC | 2024-11-14 | — | — | US | disclosed |
| US-12084472-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | ARDELYX, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | ENANTA PHARM INC (US) | 2024-08-08 | — | — | US | disclosed |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-06 | — | — | US | disclosed |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-112094266-B | Pyrrolopyridinone compound, preparation method, composition and application thereof | 中国科学院上海药物研究所 | 2023-03-21 | — | — | CN | disclosed |
| EP-2178840-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | Almirall, S.A. (ES) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008124848-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1034164-B1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| EP-1034164-A4 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-1034164-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999026921-A1 | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459942-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ENPP2 237/4885LIPE 4751/4885ORAI1 2768/4885 |
| US-20240262828-A1 | Functionalized Heterocycles as Antiviral Agents | HCCS, HAVCR2, HDGF | ENPP2 3296/4885LIPE 4333/4885ORAI1 3981/4885 |
| US-20250066410-A1 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, GLP1R | ENPP2 1381/4885LIPE 468/4885ORAI1 2688/4885 |
| US-20250388615-A9 | SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS | GPR119, GIPR, FFAR3 | ENPP2 2065/4885LIPE 442/4885ORAI1 3481/4885 |
| US-11891393-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ENPP2 3296/4885LIPE 4333/4885ORAI1 3981/4885 |
| US-20240376095-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ENPP2 279/4885LIPE 4755/4885ORAI1 2783/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | ENPP2 1558/4885LIPE 4104/4885ORAI1 4044/4885 |
| US-11739087-B2 | Inhibiting (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ENPP2 237/4885LIPE 4751/4885ORAI1 2768/4885 |
| US-12084472-B2 | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists | GPR119, GIPR, GLP1R | ENPP2 1381/4885LIPE 468/4885ORAI1 2688/4885 |
| US-12264159-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ENPP2 3296/4885LIPE 4333/4885ORAI1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.